Drugs & Therapy Perspectives

, Volume 23, Issue 11, pp 9–12 | Cite as

The pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents is effective and relatively safe

Disease Management


  1. 1.
    Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157(5): 816–8PubMedCrossRefGoogle Scholar
  2. 2.
    Hazell P. Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations. CNS Drugs 2007; 21 (1) 37-46Google Scholar
  3. 3.
    British Medical Association and the Royal Pharmaceutical Society of Great Britian. British national formulary. No. 53. London: BMJ Publishing Group Ltd and RPS Publishing, 2007 MarGoogle Scholar
  4. 4.
    WoltersKluwer Health Inc. Facts & comparisons 4.0 [online]. Available from URL: http://online.factsandcomparisons.com [Accessed 2007 Jun 20]
  5. 5.
    Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30(1): 17–26PubMedCrossRefGoogle Scholar
  6. 6.
    Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis. CMAJ 2001; 165(11): 1475–88PubMedGoogle Scholar
  7. 7.
    Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: technology appraisal 98. London: National Institute for Health and Clinical Excellence, 2006 MarGoogle Scholar
  8. 8.
    Greenhill LL, Abikoff HB, Aanold E, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 34(10): 1304–13CrossRefGoogle Scholar
  9. 9.
    Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160(2): 82–90CrossRefGoogle Scholar
  10. 10.
    Cox DJ, Humphrey JW, Merkel RL, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 2004; 17(4): 235–9PubMedCrossRefGoogle Scholar
  11. 11.
    Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006; 45: 149–57PubMedCrossRefGoogle Scholar
  12. 12.
    Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J Addict Dis 2004; 23(4): 31–40PubMedCrossRefGoogle Scholar
  13. 13.
    Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 2005; 15(5): 751–63PubMedCrossRefGoogle Scholar
  14. 14.
    Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99(8): 979–82PubMedCrossRefGoogle Scholar
  15. 15.
    El-Zein R, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett 2005; 230(2): 284–91PubMedCrossRefGoogle Scholar
  16. 16.
    Selby J, Friedman GD, Fireman BH. Screening precription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49(20): 5736–47PubMedGoogle Scholar
  17. 17.
    Institute for Clinical Systems Improvement. Health care guideline: diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. 7th ed. [online]. Available from URL: http://www.icsi.org [Accessed 2007 May 11]

Copyright information

© Adis Data Information BV 2007

Personalised recommendations